RecruitingPHASE1, PHASE2NCT06517888

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Studying Vestibular schwannoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Akouos, Inc.
Principal Investigator: Aaron Tward, MD
Eli Lilly and Company
Intervention: AAVAnc80-antiVEGF via Akouos Delivery Device(combination_product)
Enrollment: 27 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2029

Study locations (4)

Johns Hopkins Hospital, Baltimore, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
Vanderbilt Bill Wilkerson Center, Nashville, Tennessee, United States
University of Texas Southwestern, Dallas, Texas, United States

Collaborators

Eli Lilly and Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06517888 on ClinicalTrials.gov

Other trials for Vestibular schwannoma

Additional recruiting or active studies for the same condition.

See all trials for Vestibular schwannoma →

← Back to all trials